Histogen Incis A Clinical Stage Biotechnology Company Based In San Diegocaliforniafounded In 2007The Company Specializes In Regenerative Medicine And Drug Developmentfocusing On Therapies That Address Infectious Diseasesliver Conditionsand Inflammatory Disordershistogen Utilizes Proprietary Bioreactor Systems To Cultivate Newborn Fibroblastsproducing Biologically Active Compounds That Mimic Embryonic Proteins And Growth Factors The Company Has Developed Two Main Product Familiesa Proprietary Liquid Complex Designed To Promote Tissue Repair And Regenerationand Exceltrixa Human Extracellular Matrix Material That Provides Cellular Supporthistogen S Pipeline Includes Emricasana Pan Caspase Inhibitor In Clinical Development For Various Conditionsand Preclinical Candidates Targeting Inflammatory Diseasesthe Company Holds 20 Patents Related To Its Technologies And Operates Through Research Driven Partnerships And Licensing Opportunities
